X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-30 | BCDA | Biocardia, Inc. | McClung David | CFO | P - Purchase | $2.08 | +4,819 | 47,950 | +11% | +$9,999 | |||||
| D | 2025-06-30 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.08 | +24,096 | 165,862 | +17% | +$49,999 | |||||
| D | 2025-06-30 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $2.08 | +72,289 | 315,875 | +30% | +$150,000 | |||||
| D | 2025-06-30 | BCDA | Biocardia, Inc. | Blank Andrew Scott | Dir | P - Purchase | $2.08 | +72,289 | 348,058 | +26% | +$150,000 | |||||
2025-07-02 | EXOZ | Exozymes Inc. | Heltzen Michael | CEO | P - Purchase | $10.22 | +1,040 | 10,629 | +11% | +$10,629 | ||||||
2025-07-01 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $5.10 | -22,000 | 1,298,391 | -2% | -$112,207 | ||||||
| D | 2025-07-01 | ATHA | Athira Pharma, Inc. | Church Kevin | Chief Scientific Officer | S - Sale+OE | $0.29 | -8,526 | 168,901 | -5% | -$2,502 | |||||
| D | 2025-07-01 | ATHA | Athira Pharma, Inc. | Litton Mark James | Pres, CEO | S - Sale+OE | $0.29 | -25,123 | 345,491 | -7% | -$7,374 | |||||
| D | 2025-07-01 | ATHA | Athira Pharma, Inc. | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $0.29 | -10,842 | 71,665 | -13% | -$3,182 | |||||
| D | 2025-07-01 | ATHA | Athira Pharma, Inc. | Worthington Mark | GC, CCO | S - Sale+OE | $0.29 | -8,526 | 111,875 | -7% | -$2,502 | |||||
| D | 2025-07-01 | ATHA | Athira Pharma, Inc. | Renninger Robert | SVP, Finance, Accounting | S - Sale+OE | $0.29 | -2,897 | 109,186 | -3% | -$850 | |||||
| D | 2025-06-30 | CADL | Candel Therapeutics, Inc. | Nichols William Garrett | Chief Medical Officer | S - Sale+OE | $5.04 | -781 | 52,493 | -1% | -$3,936 | |||||
2025-06-27 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $30.47 | -200,000 | 3,657,349 | -5% | -$6,093,000 | ||||||
2025-06-30 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $110.45 | -10,000 | 615,725 | -2% | -$1,104,484 | ||||||
2025-06-30 | PRME | Prime Medicine, Inc. | Liu David R. | 10% | P - Purchase | $2.52 | +21,000 | 20,240,945 | 0% | +$52,830 | ||||||
| D | 2025-04-28 | PLUR | Pluri Inc. | Manieu Alexandre Weinstein | Dir, 10% | P - Purchase | $4.61 | +976,139 | 1,394,198 | +233% | +$4,500,001 | |||||
| D | 2025-06-30 | KYMR | Kymera Therapeutics, Inc. | Baker Bros. Advisors LP | Dir | P - Purchase | $44.00 | +655,500 | 6,117,295 | +12% | +$28,842,000 | |||||
2025-06-26 | CDTX | Cidara Therapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $44.00 | +2,272,727 | 3,365,523 | +208% | +$99,999,988 | ||||||
2025-06-25 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.00 | +6,000 | 416,371 | +1% | +$12,000 | ||||||
2025-06-25 | DTIL | Precision Biosciences Inc | Brown Melinda | Dir | P - Purchase | $4.14 | +1,682 | 20,565 | +9% | +$6,963 | ||||||
2025-06-25 | DTIL | Precision Biosciences Inc | Buehler Kevin | Dir | P - Purchase | $4.16 | +5,076 | 28,137 | +22% | +$21,116 | ||||||
| M | 2025-06-24 | PASG | Passage Bio, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $0.34 | -583,657 | 6,066,343 | -9% | -$197,239 | |||||
| D | 2025-06-23 | SRRK | Scholar Rock Holding Corp | Flier Jeffrey S. | Dir | S - Sale+OE | $32.58 | -31,452 | 35,206 | -47% | -$1,024,722 | |||||
| DM | 2025-06-20 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $53.09 | -60,000 | 733,719 | -8% | -$3,185,280 | |||||
| D | 2025-06-20 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $35.76 | -1,678 | 645,782 | 0% | -$59,997 | |||||
2025-06-20 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $35.76 | -292 | 127,603 | 0% | -$10,440 | ||||||
2025-06-20 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $35.76 | -230 | 104,737 | 0% | -$8,224 | ||||||
| M | 2025-06-18 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.11 | +4,002 | 410,371 | +1% | +$8,425 | |||||
2025-06-23 | PRME | Prime Medicine, Inc. | Liu David R. | 10% | P - Purchase | $2.16 | +21,000 | 20,219,945 | 0% | +$45,402 | ||||||
2025-06-20 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $39.61 | -1,912 | 54,093 | -3% | -$75,736 | ||||||
2025-06-20 | ALEC | Alector, Inc. | Yaffe Kristine | Dir | S - Sale | $1.44 | -1,000 | 95,409 | -1% | -$1,440 | ||||||
| M | 2025-06-18 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $30.19 | -334,801 | 3,857,349 | -8% | -$10,107,818 | |||||
| D | 2025-06-16 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $20.81 | -21,000 | 3,768,233 | -1% | -$437,010 | |||||
| D | 2025-06-17 | TARS | Tarsus Pharmaceuticals, Inc. | Farrow Jeffrey S | See Remarks | S - Sale+OE | $40.42 | -13,608 | 36,704 | -27% | -$550,035 | |||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale | $39.83 | -3,510 | 150,675 | -2% | -$139,803 | ||||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $39.83 | -13,496 | 935,172 | -1% | -$537,546 | ||||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $39.83 | -1,878 | 56,005 | -3% | -$74,801 | ||||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale | $39.83 | -2,170 | 113,314 | -2% | -$86,431 | ||||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $39.83 | -4,289 | 289,414 | -1% | -$170,831 | ||||||
2025-06-16 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $33.48 | -94 | 104,967 | 0% | -$3,147 | ||||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Wei Lin | Chief Medical Officer | S - Sale | $39.83 | -2,173 | 90,499 | -2% | -$86,551 | ||||||
| D | 2025-06-17 | KOD | Kodiak Sciences Inc. | Borgeson John A. | See Remarks | S - Sale+OE | $3.65 | -723 | 183,316 | 0% | -$2,640 | |||||
2025-06-16 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $110.17 | -2,500 | 165,110 | -1% | -$275,425 | ||||||
2025-06-16 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $110.17 | -3,000 | 120,168 | -2% | -$330,510 | ||||||
2025-06-16 | SRRK | Scholar Rock Holding Corp | Peng Katie | Dir | S - Sale | $31.97 | -3,031 | 34,920 | -8% | -$96,888 | ||||||
2025-06-16 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $32.00 | -3,668 | 139,561 | -3% | -$117,381 | ||||||
2025-06-16 | SRRK | Scholar Rock Holding Corp | Parlavecchio Caryn | CHRO | S - Sale | $32.00 | -6,186 | 157,642 | -4% | -$197,961 | ||||||
2025-06-16 | SRRK | Scholar Rock Holding Corp | Ho Junlin | GC | S - Sale | $32.00 | -7,442 | 222,569 | -3% | -$238,154 | ||||||
| D | 2025-06-16 | TARS | Tarsus Pharmaceuticals, Inc. | Lin Elizabeth Yeu | Chief Medical Officer | S - Sale+OE | $41.08 | -1,006 | 35,600 | -3% | -$41,326 | |||||
| DM | 2025-06-12 | ADMA | Adma Biologics, Inc. | Elms Steve | Dir | S - Sale+OE | $20.74 | -425,621 | 2,119,060 | -17% | -$8,829,333 | |||||
2025-06-16 | PRME | Prime Medicine, Inc. | Liu David R. | 10% | P - Purchase | $1.49 | +21,000 | 20,198,945 | 0% | +$31,196 | ||||||
| D | 2025-06-13 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $14.33 | +3,488 | 558,114 | +1% | +$49,983 | |||||
2025-06-13 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $7.70 | +107 | 38,885 | 0% | +$824 | ||||||
2025-06-11 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.00 | +524 | 406,369 | 0% | +$1,048 | ||||||
2025-06-12 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $8.70 | +103 | 38,675 | 0% | +$896 | ||||||
2025-06-11 | PRME | Prime Medicine, Inc. | Liu David R. | 10% | P - Purchase | $1.60 | +21,000 | 20,177,945 | 0% | +$33,590 | ||||||
2025-06-10 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $29.00 | -350,000 | 4,192,150 | -8% | -$10,150,000 | ||||||
2025-06-11 | MRNA | Moderna, Inc. | Hussain Abbas | Dir | S - Sale | $28.00 | -312 | 580 | -35% | -$8,736 | ||||||
2025-06-10 | ALLO | Allogene Therapeutics, Inc. | Messemer Deborah M. | Dir | S - Sale | $1.42 | -36,885 | 107,431 | -26% | -$52,377 | ||||||
2025-06-09 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $1.99 | +138 | 405,845 | 0% | +$275 | ||||||
| DM | 2025-06-09 | ITOS | Iteos Therapeutics, Inc. | Detheux Michel | CEO | S - Sale+OE | $10.03 | -104,565 | 247,930 | -30% | -$1,048,264 | |||||
2025-06-09 | ADMA | Adma Biologics, Inc. | Guiheen Lawrence P. | Dir | S - Sale | $20.96 | -20,000 | 145,820 | -12% | -$419,200 | ||||||
| D | 2025-06-10 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $67.36 | -1,500 | 0 | -100% | -$101,040 | |||||
2025-06-09 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $0.62 | -4,904 | 405,982 | -1% | -$3,050 | ||||||
2025-06-09 | IPSC | Century Therapeutics, Inc. | Farid Adrienne | Chief Operations Officer | S - Sale | $0.62 | -552 | 250,141 | 0% | -$343 | ||||||
2025-06-09 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | S - Sale | $0.62 | -475 | 1,681,783 | 0% | -$295 | ||||||
2025-06-09 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $0.62 | -526 | 484,820 | 0% | -$327 | ||||||
2025-06-09 | TARS | Tarsus Pharmaceuticals, Inc. | Mottiwala Aziz | Chief Commercial Officer | S - Sale | $43.76 | -17,500 | 47,557 | -27% | -$765,800 | ||||||
| D | 2025-06-11 | KYMR | Kymera Therapeutics, Inc. | Ridloff Elena | Dir | S - Sale+OE | $50.00 | -4,500 | 0 | -100% | -$225,000 | |||||
| D | 2025-06-09 | TECH | Bio-Techne Corp | Herr Amy E. | Dir | S - Sale+OE | $49.77 | -1,280 | 3,016 | -30% | -$63,705 | |||||
| D | 2025-06-09 | ADMA | Adma Biologics, Inc. | Grossman Jerrold B | Dir | S - Sale+OE | $21.31 | -10,000 | 570,901 | -2% | -$213,100 | |||||
2025-06-06 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $31.75 | -257 | 105,061 | 0% | -$8,160 | ||||||
2025-06-06 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $31.75 | -853 | 127,895 | -1% | -$27,083 | ||||||
| D | 2025-06-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $31.75 | -2,170 | 647,460 | 0% | -$68,898 | |||||
2025-06-06 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $31.75 | -225 | 49,966 | 0% | -$7,144 | ||||||
2025-06-06 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.00 | +11,100 | 405,707 | +3% | +$22,200 | ||||||
2025-06-09 | TVGN | Tevogen Bio Holdings Inc. | Saadi Ryan H. | CEO, 10% | S - Sale | $1.23 | -1,438,206 | 117,008,377 | -1% | -$1,768,993 | ||||||
2025-06-06 | MGX | Metagenomi, Inc. | Wein Matthew | See Remarks | S - Sale | $1.75 | -199 | 16,693 | -1% | -$348 | ||||||
2025-06-06 | MGX | Metagenomi, Inc. | Noonberg Sarah B. | Chief Medical Officer | S - Sale | $1.75 | -5,239 | 109,135 | -5% | -$9,168 | ||||||
2025-06-06 | MGX | Metagenomi, Inc. | Wapnick Pamela | CFO | S - Sale | $1.75 | -1,576 | 72,108 | -2% | -$2,758 | ||||||
2025-06-06 | MGX | Metagenomi, Inc. | Thomas Brian C. | CEO | S - Sale | $1.75 | -10,785 | 2,517,491 | 0% | -$18,874 | ||||||
2025-06-06 | MGX | Metagenomi, Inc. | Irish Jian | See Remarks | S - Sale | $1.75 | -6,390 | 315,543 | -2% | -$11,183 | ||||||
| DM | 2025-06-04 | ITOS | Iteos Therapeutics, Inc. | Detheux Michel | CEO | S - Sale+OE | $10.15 | -156,847 | 135,903 | -54% | -$1,592,520 | |||||
| DM | 2025-06-04 | ITOS | Iteos Therapeutics, Inc. | Hallal David | Dir | S - Sale+OE | $10.15 | -114,682 | 0 | -100% | -$1,164,405 | |||||
2025-06-04 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $36.96 | -2,725 | 241,723 | -1% | -$100,716 | ||||||
2025-06-05 | AMGN | Amgen Inc | Khosla Rachna | SVP, Business Development | S - Sale | $289.68 | -1,500 | 8,162 | -16% | -$434,520 | ||||||
2025-06-05 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $7.78 | -10,000 | 65,462 | -13% | -$77,800 | ||||||
2025-06-05 | IOVA | Iovance Biotherapeutics, Inc. | Kirby Daniel Gordon | Chief Commercial Officer | P - Purchase | $1.84 | +30,000 | 30,000 | New | +$55,200 | ||||||
2025-06-02 | EXEL | Exelixis, Inc. | Eckhardt Sue Gail | Dir | S - Sale | $42.74 | -18,838 | 21,380 | -47% | -$805,140 | ||||||
2025-06-03 | EXEL | Exelixis, Inc. | Wyszomierski Jack L | Dir | S - Sale | $43.09 | -7,535 | 358,882 | -2% | -$324,683 | ||||||
2025-06-03 | EDIT | Editas Medicine, Inc. | Parison Amy | SVP, CFO | S - Sale | $1.72 | -446 | 17,506 | -2% | -$769 | ||||||
2025-06-03 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $1.72 | -726 | 69,519 | -1% | -$1,252 | ||||||
2025-06-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $1.72 | -15,192 | 280,282 | -5% | -$26,196 | ||||||
| M | 2025-06-02 | CDTX | Cidara Therapeutics, Inc. | Mineo Chrysa | Dir | P - Purchase | $22.26 | +3,320 | 3,320 | New | +$73,896 | |||||
2025-06-02 | ALEC | Alector, Inc. | Grasso Marc | CFO | S - Sale | $1.34 | -16,488 | 296,072 | -5% | -$22,068 | ||||||
2025-06-02 | ALEC | Alector, Inc. | Kenkare-Mitra Sara | Pres, Head of R, D | S - Sale | $1.34 | -23,890 | 512,252 | -4% | -$31,974 | ||||||
2025-06-02 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $1.34 | -52,087 | 6,345,032 | -1% | -$69,713 | ||||||
2025-06-03 | GLUE | Monte Rosa Therapeutics, Inc. | Dunn Edmund | Principal Accounting Officer | S - Sale | $4.45 | -2,062 | 23,732 | -8% | -$9,174 | ||||||
| D | 2025-06-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Chief Medical Officer | S - Sale+OE | $40.09 | -10,000 | 66,237 | -13% | -$400,900 | |||||
2025-05-30 | TSHA | Taysha Gene Therapies, Inc. | Manning Paul B | 10% | P - Purchase | $2.75 | +750,000 | 25,601,111 | +3% | +$2,062,500 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |